Abstract
The prime difference between generics and biosimilars is that while generics contain the exact active ingredient as in the originator product, biosimilars are only “similar” and not “identical” to the originator biological medicine. This difference appears due to the nature of the biopharmaceutical medicines which are extremely complex to manufacture (it is not possible to make an exact copy of a biotech medicine in the same way as a traditional chemical molecule can be copied). In fact, it is widely accepted that for biopharmaceuticals, the “process is the product”. Minor changes during the manufacturing process can have critical consequences in the patients. The vast majority of the biopharmaceuticals on the market are produced by genetic engineering using various recombinant expression systems. Most of the recombinant proteins that have been granted marketing approval to date are produced either in E. Coli or in recombinant mammalian cell lines. Several approaches may be undertaken to determine biopharmaceuticals potency. Bioassays represent the most relevant potency-determining assay, as they directly assess the biological activity of the product. These assays involve applying a known quantity of the substance to be analyzed to a biological system which responds to this applied stimulus. The response is measured quantitatively, allowing an activity value to be assigned to the substance being assayed.
Current Pharmaceutical Biotechnology
Title: Global Vision about the Biological Medicinal Products: Biosimilars (April, 2009)
Volume: 10 Issue: 8
Author(s): Leyre Zuniga and Begona Calvo
Affiliation:
Abstract: The prime difference between generics and biosimilars is that while generics contain the exact active ingredient as in the originator product, biosimilars are only “similar” and not “identical” to the originator biological medicine. This difference appears due to the nature of the biopharmaceutical medicines which are extremely complex to manufacture (it is not possible to make an exact copy of a biotech medicine in the same way as a traditional chemical molecule can be copied). In fact, it is widely accepted that for biopharmaceuticals, the “process is the product”. Minor changes during the manufacturing process can have critical consequences in the patients. The vast majority of the biopharmaceuticals on the market are produced by genetic engineering using various recombinant expression systems. Most of the recombinant proteins that have been granted marketing approval to date are produced either in E. Coli or in recombinant mammalian cell lines. Several approaches may be undertaken to determine biopharmaceuticals potency. Bioassays represent the most relevant potency-determining assay, as they directly assess the biological activity of the product. These assays involve applying a known quantity of the substance to be analyzed to a biological system which responds to this applied stimulus. The response is measured quantitatively, allowing an activity value to be assigned to the substance being assayed.
Export Options
About this article
Cite this article as:
Zuniga Leyre and Calvo Begona, Global Vision about the Biological Medicinal Products: Biosimilars (April, 2009), Current Pharmaceutical Biotechnology 2009; 10 (8) . https://dx.doi.org/10.2174/138920109789978702
DOI https://dx.doi.org/10.2174/138920109789978702 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ameliorative Effect of α-Tocopherol and Selenium on Effects of Malathion on Plasmatic Biochemical Indices and Lesions in the Liver of Rats
Current Pharmaceutical Analysis The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design The Development and Progression of Atherosclerosis: Evidence supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Recent Patents on Anti-Cancer Drug Discovery Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNA 21 Emerging Role in Diabetic Complications: A Critical Update
Current Diabetes Reviews Realising Heart Regeneration
Current Tissue Engineering (Discontinued) PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Diabetes, Sexual Dysfunction and Therapeutic Exercise: A 20 Year Review
Current Diabetes Reviews Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Dietary Lipid Absorption (Guest Editors: C.C. DiRusso and P.N. Black)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study
Current Vascular Pharmacology Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?
Current Clinical Pharmacology Exploration of SQC Formula Effect on Type 2 Diabetes Mellitus by Whole Transcriptome Profile in Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets